Shenzhen NewDEL Biotech Co., Ltd.
About US
About us
Founded in April 2021, it is the first biotech company incubated by the Guangdong Innovation Center for Small Molecule Drug Discovery (the "Small Molecule Center"). Focusing on the major needs of innovation and development in the pharmaceutical industry and common key technologies in the industry, the Small Molecule Center is committed to breaking through the bottleneck of key common technologies in the industrial chain, promoting the transformation of results, and creating a collaborative innovation ecosystem.
The company has two new generations of DNA encoded library technology for drug discovery,DEL2.0 (Live Cell DEL) and DEL 3.0 (SmartDEL), which has significant advantages and differentiation. Relying on our DEL technology with independent intellectual property rights, the company has established a full-life cycle system focusing on the design, research and development and industrialization of FIC/BIC drugs for unmet clinical needs, and is committed to becoming an international leading and distinctive biotech company.
2021
Be established in
50 +
Technical patent
5 +
Expert team
Technology platform
Core technology
DNA Coding Compound Library (DEL) technology takes inspiration from monoclonal antibody discovery technology and combines the advantages of combinatorial chemistry and high-throughput screening technology to efficiently find small molecules with high affinity to target proteins.
Technological advantage
Wider range: The screening range of most DNA coding molecular libraries is only limited to purified protein targets, and it is not possible to screen targets that are more biologically significant and more relevant to real diseases.
Technology Platform
Core technology
DNA encoded Library (DEL) technology takes inspiration from monoclonal antibody discovery technology, combines the advantages of combinatorial chemistry and high-throughput screening technology, and efficiently finds small molecules with high affinity for target proteins.
Core technology
——
DNA encoded Library (DEL) technology takes inspiration from monoclonal antibody discovery technology and combines the advantages of combinatorial chemistry and high-throughput screening technology to efficiently find small molecules with high affinity to target proteins.
The DEL2.0 technology platform developed by NewDEL Biotech can be applied to live cell-based screening; This technology does not require the expression and purification of target proteins, and compared with the previous generation of biochemical models, the screening of DEL2.0 is closer to the real environment in vivo, thus making the screening success rate higher.
NewDEL Biotech is upgrading the new drug development technology platform around DEL technology,
SmartDEL (DEL3.0) with one-stop new drug discovery platform based on DEL big data empowered by Al has been implemented,while other DEL+x
platform (DEL+Protac,DEL+Peptide,etc) is under development.
Technological advantage
Wider range: The screening range of the vast majority of DNA encoded molecular libraries is only limited to purified protein targets, and it is not possible to screen biological activities that are more biologically significant and more relevant to the real disease environment.
Technological advantage
——
Patented technology: The live-cell based DEL screening patented technology
Single-Stranded DNA encoding:Less signal noise,higher hit rate,versatile for new technology development
Wider range: The screening range of most DNA encoded molecular libraries is only limited to purified protein targets, and it is not possible to screen biological activities that are more biologically significant and more relevant to the real disease environment. Our technology can screen drugs in living cells, clinicopathological tissues and other levels, with a wide range of screening and high technical barriers.
High accuracy: screening targets such as membrane proteins that are difficult to purify, closer to the physiological state screening settinq.
New drug pipeline
New drug pipeline
Contact us
Contact: Miss Zhu
Email: nd@newdel.com.cn
Tel: 0755-28199327
Postal Code: 518110
Add: A1503, Building 1, Yinxing Zhijie Phase II, No. 1301-76, Xinlan Community, Guanlan Street, Longhua District, Shenzhen
Contact us
Contact: Manager Lu
Tel: 0755-28199301
Email: nd@newdel.com.cn
Postal Code: 518110
Add: A1503,Building 1-A YESEN Intelligent Community,1301-76 Guanguang Rd.，Longhua Dist.,Shenzhen,Guangdong,China
Copyright © 2021-2024 Shenzhen NewDEL Biotech Co., Ltd.
Guangdong ICP for 2022125782
Contact: Mr. Lu Email：nd@newdel.com.cn 
A1503 Building 1-A YESEN 